Chinmay BagweChinmayBagwe

Takeda Pharm. Co. Ltd. et al. v. Norwich Pharms., Inc., No. 20-8966 (D.N.J.) (Trial Victory) aff’d, 23-1374 (Fed. Cir.) Represented Takeda in a Hatch-Waxman trial and appeal against Norwich concerning Takeda’s blockbuster ADHD drug Vyvanse®. All of Takeda’s asserted claims across nine Orange Book-listed patents were held infringed, not invalid, and enforceable.

Astellas US LLC et al. v. Curia Missouri Inc. et al., No. 22-0199 (D. Del.) Represented Curia in a patent litigation against plaintiffs Astellas and Gilead concerning plaintiffs’ pharmacologic stress testing agent Lexiscan®. Plaintiffs voluntarily dismissed the case pending Curia’s case-dispositive motion to dismiss and in light of plaintiffs’ defeat at trial and on appeal in a related case: Astellas US LLC et al. v. Hospira, Inc., No. 18-1675 (D. Del.) (finding that Curia’s API and manufacturing process do not infringe the asserted patent claims) aff’d, 22-1878 (Fed. Cir.).

AbbVie Endocrine Inc. v. Takeda Pharm. Co. Ltd., No. 20-0953 (Del. Ch.) (Injunction Trial Victory) Represented Takeda in the injunction phase of a trial arising from a breach of contract dispute against AbbVie concerning AbbVie’s endometriosis and prostate cancer treatment Lupron Depot®. AbbVie’s request for expedited injunctive relief was denied.